Nektar Therapeutics (NKTR) Equity Average: 2011-2025
Historic Equity Average for Nektar Therapeutics (NKTR) over the last 14 years, with Sep 2025 value amounting to $30.4 million.
- Nektar Therapeutics' Equity Average fell 52.65% to $30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.4 million, marking a year-over-year decrease of 52.65%. This contributed to the annual value of $95.9 million for FY2024, which is 61.47% down from last year.
- As of Q3 2025, Nektar Therapeutics' Equity Average stood at $30.4 million, which was up 681.26% from -$5.2 million recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' Equity Average registered a high of $1.0 billion during Q1 2021, and its lowest value of -$5.2 million during Q2 2025.
- Over the past 3 years, Nektar Therapeutics' median Equity Average value was $103.2 million (recorded in 2024), while the average stood at $114.5 million.
- Data for Nektar Therapeutics' Equity Average shows a maximum YoY crashed of 105.07% (in 2025) over the last 5 years.
- Over the past 5 years, Nektar Therapeutics' Equity Average (Quarterly) stood at $740.5 million in 2021, then plummeted by 47.41% to $389.4 million in 2022, then crashed by 62.72% to $145.2 million in 2023, then slumped by 62.25% to $54.8 million in 2024, then slumped by 52.65% to $30.4 million in 2025.
- Its Equity Average stands at $30.4 million for Q3 2025, versus -$5.2 million for Q2 2025 and $37.2 million for Q1 2025.